- Home
- VRAX vs CYCN Comparison
VRAX vs CYCN Comparison
Compare VRAX & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- CYCN
- Stock Information
- Founded
- VRAX 2013
- CYCN 2018
- Country
- VRAX United Kingdom
- CYCN United States
- Employees
- VRAX N/A
- CYCN N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- CYCN Health Care
- Exchange
- VRAX Nasdaq
- CYCN Nasdaq
- Market Cap
- VRAX 7.3M
- CYCN 8.4M
- IPO Year
- VRAX 2022
- CYCN N/A
- Fundamental
- Price
- VRAX $2.04
- CYCN $3.36
- Analyst Decision
- VRAX
- CYCN
- Analyst Count
- VRAX 0
- CYCN 0
- Target Price
- VRAX N/A
- CYCN N/A
- AVG Volume (30 Days)
- VRAX 291.7K
- CYCN 5.8M
- Earning Date
- VRAX 02-05-2025
- CYCN 03-04-2025
- Dividend Yield
- VRAX N/A
- CYCN N/A
- EPS Growth
- VRAX N/A
- CYCN N/A
- EPS
- VRAX N/A
- CYCN N/A
- Revenue
- VRAX $84,872.00
- CYCN $194,000.00
- Revenue This Year
- VRAX $5,169.18
- CYCN N/A
- Revenue Next Year
- VRAX $66.97
- CYCN N/A
- P/E Ratio
- VRAX N/A
- CYCN N/A
- Revenue Growth
- VRAX 7.03
- CYCN N/A
- 52 Week Low
- VRAX $0.60
- CYCN $1.27
- 52 Week High
- VRAX $9.00
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- VRAX 53.40
- CYCN 49.03
- Support Level
- VRAX $1.58
- CYCN $2.81
- Resistance Level
- VRAX $2.29
- CYCN $4.80
- Average True Range (ATR)
- VRAX 0.24
- CYCN 0.75
- MACD
- VRAX 0.00
- CYCN -0.00
- Stochastic Oscillator
- VRAX 66.22
- CYCN 26.84
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.